AQR Capital Management LLC Sells 19511 Shares of Thomson Reuters Corp (NYSE:TRI)

Bridgewater Associates LP raised its stake in shares of Thomson Reuters by 16.6% during the 3rd quarter. Bridgewater Associates LP now owns …

Thomson Reuters logoAQR Capital Management LLC trimmed its stake in shares of Thomson Reuters Corp (NYSE:TRI) (TSE:TRI) by 4.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 460,285 shares of the business services provider’s stock after selling 19,511 shares during the quarter. AQR Capital Management LLC owned 0.08% of Thomson Reuters worth $20,988,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TRI. Deutsche Bank AG raised its stake in Thomson Reuters by 13.8% during the 3rd quarter. Deutsche Bank AG now owns 683,260 shares of the business services provider’s stock valued at $31,207,000 after acquiring an additional 82,605 shares during the last quarter. Cerebellum GP LLC purchased a new position in shares of Thomson Reuters during the 3rd quarter worth approximately $190,000. Bridgewater Associates LP raised its stake in shares of Thomson Reuters by 16.6% during the 3rd quarter. Bridgewater Associates LP now owns 124,094 shares of the business services provider’s stock worth $5,658,000 after buying an additional 17,693 shares in the last quarter. Northern Trust Corp raised its stake in shares of Thomson Reuters by 4.8% during the 2nd quarter. Northern Trust Corp now owns 516,102 shares of the business services provider’s stock worth $20,809,000 after buying an additional 23,457 shares in the last quarter. Finally, Stevens Capital Management LP raised its stake in shares of Thomson Reuters by 209.3% during the 3rd quarter. Stevens Capital Management LP now owns 75,764 shares of the business services provider’s stock worth $3,461,000 after buying an additional 51,267 shares in the last quarter. 33.41% of the stock is owned by hedge funds and other institutional investors.

NYSE:TRI traded up $0.42 during mid-day trading on Monday, hitting $50.89. The company had a trading volume of 536,765 shares, compared to its average volume of 603,041. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.45 and a quick ratio of 2.45. Thomson Reuters Corp has a 1 year low of $40.25 and a 1 year high of $54.15. The firm has a market capitalization of $25.70 billion, a PE ratio of 18.44, a price-to-earnings-growth ratio of 4.47 and a beta of 0.54.

Thomson Reuters (NYSE:TRI) (TSE:TRI) last released its quarterly earnings data on Tuesday, November 6th. The business services provider reported $0.11 EPS for the quarter, beating the consensus estimate of $0.04 by $0.07. Thomson Reuters had a return on equity of 6.10% and a net margin of 16.21%. The company had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same period last year, the company posted $0.27 earnings per share. The firm’s revenue was up 1.6% compared to the same quarter last year. Equities analysts anticipate that Thomson Reuters Corp will post 0.64 EPS for the current year.

A number of equities research analysts recently weighed in on the company. Bank of America restated a “neutral” rating and issued a $48.00 price target on shares of Thomson Reuters in a report on Wednesday, October 10th. Morgan Stanley set a $51.00 price target on Thomson Reuters and gave the stock a “buy” rating in a report on Monday, October 15th. Zacks Investment Research upgraded Thomson Reuters from a “hold” rating to a “buy” rating and set a $51.00 price target on the stock in a report on Wednesday, October 17th. Goldman Sachs Group assumed coverage on Thomson Reuters in a report on Thursday, October 18th. They issued a “neutral” rating on the stock. Finally, TD Securities restated a “buy” rating and issued a $69.00 price target on shares of Thomson Reuters in a report on Wednesday, November 7th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the company’s stock. Thomson Reuters has an average rating of “Hold” and an average target price of $52.91.

WARNING: “AQR Capital Management LLC Sells 19,511 Shares of Thomson Reuters Corp (NYSE:TRI)” was originally reported by Modern Readers and is the sole property of of Modern Readers. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.modernreaders.com/news/2019/01/21/aqr-capital-management-llc-reduces-position-in-thomson-reuters-corp-tri.html.

About Thomson Reuters

Thomson Reuters Corporation provides news and information for professional markets worldwide. The company operates through three segments: Financial & Risk, Legal, and Tax & Accounting. It sells electronic content and services to professionals primarily on a subscription basis. The Financial & Risk segment offers critical news, information, and analytics enabling transactions and connecting communities of trading, investment, financial, and corporate professionals.

Featured Story: Determine Your Level of Risk Tolerance

Institutional Ownership by Quarter for Thomson Reuters (NYSE:TRI)

Receive News & Ratings for Thomson Reuters Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Thomson Reuters and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

As of February, 8 The EPS for Cameco Corporation (CCO) Expected At $0.25

Cameco Corporation (TSE:CCO)’s earnings report is anticipated by … 2018, “Canopy Growth Corp, Aurora Cannabis Inc Lead Cannabis Sector Surge …

Cameco Corporation (TSE:CCO) Corporate Logo

Cameco Corporation (TSE:CCO)’s earnings report is anticipated by WallStreet on February, 8, Faxor reports. Analysts forecast $0.25 EPS, which is $0.21 down or 45.65 % from 2018’s $0.46 EPS. The profit will be $98.95 million for T_CCO if $0.25 EPS becomes true. Wall Street predicts 525.00 % EPS growth as of February, 8. CCO is reaching $15.78 during the last trading session, after increased 0.32%.Cameco Corporation has volume of 169,792 shares. Since January 22, 2018 CCO has 0.00% and is . CCO by 0.00% the S&P500.

Cameco Corporation produces and sells uranium worldwide.The company has $6.25 billion market cap. It operates through three divisions: Uranium, Fuel Services, and NUKEM.Last it reported negative earnings. The Uranium segment is involved in the exploration for, mining, and milling, as well as purchase and sale of uranium concentrates.

For more Cameco Corporation (TSE:CCO) news published briefly go to: Midasletter.com, Midasletter.com, Midasletter.com, Midasletter.com or Midasletter.com. The titles are as follows: “Aurora Cannabis Inc (TSE:ACB) Cannabis Bigger Than Booze – Midas Letter” published on August 09, 2018, “VIDEO: Aphria Inc (TSE:APH) CEO on Molson Coors Canada Cannabis Deal – Midas Letter” on August 08, 2018, “Aurora Cannabis Inc Nearing A Mass Inflection Point Of Support – Midas Letter” with a publish date: August 14, 2018, “Canopy Growth Corp, Aurora Cannabis Inc Lead Cannabis Sector Surge – Midas Letter” and the last “Canopy Growth Corp (TSE:WEED) CEO Bruce Linton Discusses Rec Growth – Midas Letter” with publication date: December 18, 2018.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

BioXcel Therapeutics, Inc. (BTAI) Analysts See $-0.34 EPS; Bridgewater Associates LP Raised By …

Bridgewater Associates Lp increased Telus Corp (TU) stake by 16.11% reported in 2018Q3 SEC filing. Bridgewater Associates Lp acquired 41,636 …

TELUS Corporation (NYSE:TU) Logo

Bridgewater Associates Lp increased Telus Corp (TU) stake by 16.11% reported in 2018Q3 SEC filing. Bridgewater Associates Lp acquired 41,636 shares as Telus Corp (TU)’s stock declined 4.93%. The Bridgewater Associates Lp holds 300,160 shares with $11.06M value, up from 258,524 last quarter. Telus Corp now has $20.83B valuation. The stock increased 0.64% or $0.22 during the last trading session, reaching $34.81. About 280,473 shares traded. TELUS Corporation (NYSE:TU) has declined 7.60% since January 21, 2018 and is downtrending. It has underperformed by 7.60% the S&P500. Some Historical TU News: 19/04/2018 – TELUS launches breathtaking 4K HDR TV — a first in Canada; 23/05/2018 – TELUS innovation takes on a major technical challenge to provide the Lower North Shore region with ultra-high-speed internet and mobile services; 10/05/2018 – TELUS announces election of directors; 08/03/2018 – Mojio accelerates connected car roll-outs with additional Series B funding from lris Capital and TELUS Ventures; 10/05/2018 – Telus 1Q Net C$412M; 10/04/2018 – TELUS CORP T.TO : RBC RAISES TARGET PRICE TO C$52 FROM C$51; 17/04/2018 – Mackenzie Ivy Canadian Adds Telus, Cuts J&J; 23/05/2018 – TELUS innovation takes on a major technical challenge to provide the Lower North Shore region with ultra-high-speed internet an; 05/04/2018 – TELUS launches Boost Wi-Fi to increase wireless internet speed and coverage at home; 27/04/2018 – TELUS partners with Neil Squire Society to increase the accessibility of smartphones and touchscreen devices

Analysts expect BioXcel Therapeutics, Inc. (NASDAQ:BTAI) to report $-0.34 EPS on February, 8.After having $-0.31 EPS previously, BioXcel Therapeutics, Inc.’s analysts see 9.68% EPS growth. The stock increased 4.46% or $0.25 during the last trading session, reaching $5.86. About 28,515 shares traded. BioXcel Therapeutics, Inc. (NASDAQ:BTAI) has 0.00% since January 21, 2018 and is . It has by 0.00% the S&P500. Some Historical BTAI News: 17/05/2018 – BioXcel Therapeutics Announces Data Presentation at ASCO 2018 Annual Meeting; 14/03/2018 ARTEMIS INVESTMENT MANAGEMENT LLP REPORTS 7.74 PCT PASSIVE STAKE IN BIOXCEL THERAPEUTICS INC AS OF MARCH 12, 2018 – SEC FILING; 14/05/2018 – BIOXCEL THERAPEUTICS INC QTRLY SHR LOSS $0.37; 26/04/2018 – BioXcel Therapeutics Announces Acceptance of Abstract at ASCO 2018 Annual Meeting; 14/05/2018 – BioXcel Therapeutics 1Q Net $4.3M; 14/05/2018 – BioXcel Therapeutics 1Q Loss/Shr 37c; 04/05/2018 – DJ BIOXCEL THERAPEUTICS INC COM, Inst Holders, 1Q 2018 (BTAI)

More notable recent BioXcel Therapeutics, Inc. (NASDAQ:BTAI) news were published by: Seekingalpha.com which released: “BioXcel +15% on Fast Track designation – Seeking Alpha” on December 27, 2018, also Seekingalpha.com with their article: “BioXcel up 20% premarket of positive dexmedetomidine data – Seeking Alpha” published on January 03, 2019, Nasdaq.com published: “BTAI On Fast Track, ERYP Faces Busy Year Ahead, CHMA Turning Heads – Nasdaq” on December 27, 2018. More interesting news about BioXcel Therapeutics, Inc. (NASDAQ:BTAI) were released by: Nasdaq.com and their article: “BTAI Up 105% In 5 Days, NVAX Gets A Shot In The Arm, BMY Snaps Up CELG – Nasdaq” published on January 04, 2019 as well as Nasdaq.com‘s news article titled: “Mid-Afternoon Market Update: Dow Down Over 500 Points; Crude Oil Falls 3.5% – Nasdaq” with publication date: December 27, 2018.

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence drug development in the fields of neuroscience and immuno-oncology in the United States. The company has market cap of $91.68 million. The firm is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It currently has negative earnings. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies.

TELUS Corporation (NYSE:TU) Ratings Chart

Related Posts:

  • No Related Posts

Perdoni, Grant and Fortunova join Capitolis

Perdoni joined Capitolis from post-trade provider Traiana, now part of CME Group, where he was head of strategic accounts. He joined the company …

Paul Perdoni, Sam Grant and Ralitza Fortunova have joined post-trade services company Capitolis, FX Week has learned.

Grant and Perdoni started at Capitolis’s London office in December.

Perdoni joined Capitolis from post-trade provider Traiana, now part of CME Group, where he was head of strategic accounts. He joined the company in 2010.

Prior to that, he spent 17 years at Thomson Reuters, most recently as a regional account director. He began his career as a junior dealer at Brazilian

Related Posts:

  • No Related Posts

Enbridge Inc (ENB) Shares Sold by Man Group plc

Man Group plc decreased its position in Enbridge Inc (NYSE:ENB) (TSE:ENB) by 66.2% in the 3rd quarter, according to the company in its most recent …

Enbridge logoMan Group plc decreased its position in Enbridge Inc (NYSE:ENB) (TSE:ENB) by 66.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,132 shares of the pipeline company’s stock after selling 29,585 shares during the quarter. Man Group plc’s holdings in Enbridge were worth $488,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ENB. Dimensional Fund Advisors LP lifted its position in Enbridge by 16.1% during the second quarter. Dimensional Fund Advisors LP now owns 910,407 shares of the pipeline company’s stock valued at $32,470,000 after purchasing an additional 126,323 shares during the period. Centaurus Financial Inc. bought a new position in Enbridge during the second quarter valued at approximately $191,000. Schroder Investment Management Group purchased a new stake in Enbridge during the second quarter valued at approximately $527,000. Mainstay Capital Management LLC ADV increased its holdings in Enbridge by 4,573.6% during the second quarter. Mainstay Capital Management LLC ADV now owns 60,102 shares of the pipeline company’s stock valued at $2,145,000 after buying an additional 58,816 shares during the last quarter. Finally, Royal London Asset Management Ltd. purchased a new stake in Enbridge during the second quarter valued at approximately $249,000. Institutional investors and hedge funds own 49.13% of the company’s stock.

Shares of ENB stock opened at $36.10 on Monday. Enbridge Inc has a 12 month low of $28.82 and a 12 month high of $39.86. The company has a market cap of $73.00 billion, a price-to-earnings ratio of 15.43, a price-to-earnings-growth ratio of 2.25 and a beta of 0.54. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.59 and a quick ratio of 0.49.

Enbridge (NYSE:ENB) (TSE:ENB) last announced its earnings results on Friday, November 2nd. The pipeline company reported $0.42 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.42. The business had revenue of $8.68 billion during the quarter, compared to analysts’ expectations of $8.28 billion. Enbridge had a net margin of 3.95% and a return on equity of 8.81%. During the same period in the prior year, the company earned $0.39 earnings per share. As a group, research analysts predict that Enbridge Inc will post 2.05 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 1st. Stockholders of record on Friday, February 15th will be paid a $0.555 dividend. The ex-dividend date of this dividend is Thursday, February 14th. This is a boost from Enbridge’s previous quarterly dividend of $0.51. This represents a $2.22 dividend on an annualized basis and a dividend yield of 6.15%. Enbridge’s dividend payout ratio is 131.82%.

A number of analysts have commented on ENB shares. Citigroup reaffirmed a “neutral” rating on shares of Enbridge in a report on Monday, September 24th. Zacks Investment Research cut shares of Enbridge from a “hold” rating to a “strong sell” rating in a report on Monday, December 31st. UBS Group started coverage on shares of Enbridge in a report on Thursday, October 4th. They set a “buy” rating for the company. Wells Fargo & Co raised shares of Enbridge from a “market perform” rating to an “outperform” rating in a report on Monday, November 5th. Finally, ValuEngine raised shares of Enbridge from a “sell” rating to a “hold” rating in a report on Tuesday, October 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $48.20.

In other news, insider Byron C. Neiles sold 64,000 shares of the stock in a transaction on Friday, December 14th. The shares were sold at an average price of $43.10, for a total value of $2,758,400.00. Following the completion of the sale, the insider now directly owns 128,665 shares of the company’s stock, valued at $5,545,461.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Albert Monaco acquired 7,569 shares of Enbridge stock in a transaction dated Tuesday, December 4th. The stock was purchased at an average cost of $43.82 per share, with a total value of $331,673.58. Following the completion of the purchase, the insider now owns 67,329 shares of the company’s stock, valued at $2,950,356.78. The disclosure for this purchase can be found here. Corporate insiders own 0.48% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Fairfield Current and is the property of of Fairfield Current. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.fairfieldcurrent.com/news/2019/01/21/enbridge-inc-enb-shares-sold-by-man-group-plc.html.

About Enbridge

Enbridge Inc operates as an energy infrastructure company in Canada and the United States. The company operates in five segments: Liquids Pipelines, Gas Transmission and Midstream, Gas Distribution, Green Power and Transmission, and Energy Services. The Liquids Pipelines segment operates common carrier and contract crude oil, natural gas liquids (NGL), and refined products pipelines and terminals.

Further Reading: How Does the Quiet Period Work?

Want to see what other hedge funds are holding ENB?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enbridge Inc (NYSE:ENB) (TSE:ENB).

Institutional Ownership by Quarter for Enbridge (NYSE:ENB)

Receive News & Ratings for Enbridge Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Enbridge and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts